Does a 3-week stall on GLP-1s really mean you're done losing weight?

What did @dietcoach4u actually say?

The creator claimed that a plateau lasting "30 or more weeks" with no weight or inch loss means you are "done losing weight on the medicines." They cited "FDA trial data" to argue that GLP-1 medications only produce weight loss for "nine to 14 months" on average. They also said that "every single jab you take, your metabolism falls," that a 30% decrease in thyroid function occurs, and that quitting leads to "60 to 70% weight regain within one year." The video ends with a pitch for their specialist practice to help patients "come off the medicines by fixing root causes."

The creator is mixing real pharmacology data with significant exaggerations and some claims that are not supported by published evidence. A few things they said land close to the truth. Several others do not.

Does the science back this up?

Partially. The claim that weight loss slows and eventually plateaus on GLP-1 therapy is well-documented. The 60-70% regain figure after stopping is also grounded in real trial data. The rest gets shakier fast.

The STEP 1 trial (Wilding et al., 2021, NEJM) showed that semaglutide 2.4mg produced most of its weight loss within the first 60-68 weeks, with a plateau forming around week 60. That is closer to 14-15 months, not a hard cutoff at 9 months. The SURMOUNT-1 trial for tirzepatide (Jastreboff et al., 2022, NEJM) showed weight loss continuing meaningfully past 12 months in many participants, with the curve still declining at week 72. So the "done at 9-14 months" framing is a rough approximation at best and actively misleading for tirzepatide users.

The regain data comes from the STEP 1 withdrawal extension (Wilding et al., 2022, Diabetes, Obesity and Metabolism), which found participants regained about two-thirds of lost weight within 12 months of stopping. That part checks out.

What did they get wrong (or right)?

The metabolic adaptation claim is real but badly overstated. Adaptive thermogenesis, the reduction in resting metabolic rate beyond what weight loss alone predicts, does occur. Müller and Bosy-Westphal (2013, Obesity Reviews) confirmed this in caloric restriction contexts. But the creator's claim that "every single jab you take, your metabolism falls" implies a linear, drug-driven metabolic crash. That is not what the literature shows. GLP-1 agonists reduce food intake; the metabolic slowdown follows the weight loss, not the injection itself.

The "30% decrease in thyroid function" claim is the most problematic statement in the video. There is no published clinical trial data supporting a 30% reduction in thyroid function as a standard outcome on GLP-1 therapy. GLP-1 receptors exist in thyroid tissue, which is why rodent studies prompted the boxed warning about thyroid C-cell tumors for semaglutide and liraglutide. But thyroid function suppression at 30% in humans is not an established finding. This claim is unverifiable at best and fear-mongering at worst.

The muscle loss concern is legitimate. Cava et al. (2017, Nutrients) and more recent analyses of GLP-1 trial data do show lean mass loss during rapid weight reduction, which is a real clinical concern worth discussing with a prescribing provider.

What should you actually know?

Plateaus on GLP-1 medications are normal and expected. They do not automatically mean the drug has stopped working or that you need to "fix hormones and metabolism" with a specialist's paid program. A plateau often reflects the drug doing exactly what it is supposed to do: reducing appetite until intake matches a new, lower equilibrium weight.

If you have been on a stable GLP-1 dose for many months with no weight change, the most evidence-supported next steps include dose optimization with your prescribing clinician, resistance training to preserve lean mass, and a reassessment of dietary protein intake. None of those require leaving your current care team.

Stopping GLP-1 therapy without medical supervision based on a social media timeline is not recommended. The regain risk is real. Any decision to taper or discontinue should happen with a licensed provider who knows your full medical history, not based on a 3-week stall benchmark from a TikTok video.